

Pacira BioSciences stock surges 44% after Viatris announces a $1.65 billion takeover deal to expand its pain treatment portfolio.
You can purchase shares of Pacira BioSciences (NASDAQ:PCRX) through any online brokerage.
Other companies in Pacira BioSciences’s space includes: Eli Lilly and Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), Merck & Co Inc (NYSE:MRK), Novartis AG (NYSE:NVS) and AstraZeneca PLC (NYSE:AZN).
Pacira BioSciences has a consensus price target of $36.07.
The stock price for Pacira BioSciences (NASDAQ: PCRX) is $36.39 last updated October 29, 2026 at 3:01 PM EDT.
There are no upcoming dividends for Pacira BioSciences.
Pacira BioSciences does not have any upcoming earnings scheduled.
There is no upcoming split for Pacira BioSciences.
Pacira BioSciences is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments:...